Do you want to read an article? Please log in or register.
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results
Macular Diseases
COMMENTED
Related content
Macular Diseases
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
Ophthalmology
Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J; TREND Study Group
doi: 10.1016/
Macular Diseases
Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study
Acta Ophthalmol
Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, López Gálvez MI, Arias Barquet L, Figueroa MS, García-Arumí J, García-Layana A, In-Eye Study Group.
doi: 10.1111/aos.14786
COMMENTED
Macular Diseases
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
JAMA Ophthalmol.
Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T
doi: 10.1001/jamaophthalmol.2019.5540.
COMMENTED
Macular Diseases
Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study
Ophthalmology.
Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, Sheidow T
doi: 10.1016/j.ophtha.
Macular Diseases
Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
Br J Ophthalmol.
Bandello F, Staurenghi G, Ricci F, Midena E, Viola F, Lupieri Sinibaldi T, Colombo L, Peruzzi E, Bassanini S
doi: 10.1136/bjophthalmol-2019-313907.
COMMENTED
Macular Diseases
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL
doi: 10.1001/jamaophthalmol.
Macular Diseases
Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial
JAMA Ophthalmol.
Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew A, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel D, Desai R, MERLOT Study Group
doi: 10.1001/jamaophthalmol.
Macular DiseasesRetinal Diseases
The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis
Am J Ophthalmol.
Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH
doi: 10.1016/j.ajo.2018.05.026.
Macular Diseases
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: THE ARIES STUDY
Retina
Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S
doi: 10.1097/IAE.0000000000003128